Category Archives: IsoRay

IsoRay gains $4.3 million in financing agreement

IsoRay, Inc., a Richland-based developer of cancer therapies, has announced a securities purchase agreement with an investor to sell $2.25 million in common stock with the potential of $2,075,000 in additional funding. IsoRay plans to use net proceeds from the … Continue reading

Posted in Company_and_Client_News, IsoRay | Leave a comment

Washington companies win $34 million in Therapeutic Discovery Project Grants

Washington life sciences companies won more than $34 million in grants through the U.S. Internal Revenue Service under the Qualifying Therapeutic Discovery Project Program which was created by the Affordable Care Act. The grant covers up to 50 percent of … Continue reading

Posted in EKOS, Funding, Healionics, Insilicos, IsoRay, Life_Sciences, NanoString_Technologies, Omeros, Pathway_Medical_Technologies, Stratos_Genomics, VisionGate | Leave a comment

IsoRay announces new applications of its Cesium-131 cancer treatment

IsoRay, Inc., a Richland-based developer of therapies for prostate and other cancers, recently announced the first Cesium-131 colon cancer treatment. The company has also provided Cesium-131 seeds to Canada for research initiatives into treatments for other cancers. In 2009 the … Continue reading

Posted in Company_and_Client_News, IsoRay, Life_Sciences, Richland, RTD, Southeast | Leave a comment

IsoRay announces a distribution agreement in Canada and another with GE subsidiary Oncura

IsoRay, Inc., a Richland-based developer of therapies for prostate and other cancers, has announced two new distribution agreements. Inter V Medical of Montreal, Quebec, Canada will have exclusive rights to sell Cesium-131 Brachytherapy seeds in Canada. GE Subsidary, Oncura will … Continue reading

Posted in Company_and_Client_News, IsoRay, Life_Sciences, Richland, RTD, Southeast | Leave a comment

IsoRay announces world’s first Cesium-131 lung implants

IsoRay, Inc., a Richland-based developer of therapies for prostate and other cancers, has announced that the world’s first Cesium-131 lung implants have been performed at Cornell Medical Center. Related external links (will open a new window): IsoRay announces world’s first … Continue reading

Posted in Company_and_Client_News, IsoRay, Life_Sciences, Richland, RTD, Southeast | Leave a comment

IsoRay announces first head and neck cancer treated with Cesium-131

IsoRay, Inc., a Richland-based developer of therapies for prostate and other cancers, has announced the first head and neck cancer treated with Cesium-131. Dwight Babcock, IsoRay’s CEO, stated “This is an important development in our strategy to significantly broaden our … Continue reading

Posted in Company_and_Client_News, IsoRay, Life_Sciences, Richland, RTD, Southeast | Leave a comment

IsoRay receives approval to market cancer therapy in Canada

IsoRay, Inc., a Richland-based developer of therapies for prostate and other cancers, has announced that Health Canada‚Äôs Therapeutic Products Directorate has approved IsoRay’s Proxcelan Cs-131 brachytherapy seeds for sale throughout Canada. In a press release, IsoRay CEO Dwight Babcock stated, … Continue reading

Posted in Company_and_Client_News, IsoRay, Life_Sciences | Leave a comment